NeoVista's epiretinal brachytherapy has been granted a compassionate waiver by the FDA to treat advanced wet age-related macular degeneration (AMD) in a patient who was not eligible for inclusion in NeoVista's current trials of the product.
NeoVista's epiretinal brachytherapy has been granted a compassionate waiver by the FDA to treat advanced wet age-related macular degeneration (AMD) in a patient who was not eligible for inclusion in NeoVista's current trials of the product.
The patient - who was treated by Dr Carl Awh, an investigator in the Phase III CABERNET trial - had been unresponsive to standard AMD treatments, including photodynamic therapy, intravitreal steroids and anti-VEGF therapy, and was at risk of total vision loss from bilateral advanced wet AMD.
Epiretinal brachytherapy, a radiation therapy, delivers a targeted dose of strontium 90 directly to lesions up to 3 mm deep and 5.4 mm wide. NeoVista's Phase II trial, evaluating brachytherapy in combination with Avastin (bevacizumab), demonstrated an improvement in mean VA in subjects using brachytherapy plus Avastin; adverse events in the Phase II trial were limited to vitrectomy-related problems and not to radiation toxicity. The ongoing Phase III trial is investigating the safety and efficacy of NeoVista's epiretinal brachytherapy with Lucentis (ranibizumab; Novartis) versus Lucentis alone.
The success of using brachytherapy in this particular compassionate case has not yet been determined.
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.